CLGN
Price
$5.39
Change
-$0.05 (-0.92%)
Updated
Mar 28, 6:59 PM EST
6 days until earnings call
CYTO
Price
$2.07
Change
-$0.28 (-11.91%)
Updated
Mar 28, 6:59 PM EST
Ad is loading...

Analysis and predictions CLGN vs CYTO

Header iconCLGN vs CYTO Comparison
Open Charts CLGN vs CYTOBanner chart's image
CollPlant Biotechnologies
Price$5.39
Change-$0.05 (-0.92%)
Volume$2.19K
CapitalizationN/A
Altamira Therapeutics
Price$2.07
Change-$0.28 (-11.91%)
Volume$143.65K
CapitalizationN/A
View a ticker or compare two or three
CLGN vs CYTO Comparison Chart

Loading...

CYTODaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
CLGN vs. CYTO commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CLGN is a Hold and CYTO is a StrongSell.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (CLGN: $5.35 vs. CYTO: $2.05)
Brand notoriety: CLGN and CYTO are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CLGN: 32% vs. CYTO: 20%
Market capitalization -- CLGN: $61.27M vs. CYTO: $3.77M
CLGN [@Biotechnology] is valued at $61.27M. CYTO’s [@Biotechnology] market capitalization is $3.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $570.99B to $0. The average market capitalization across the [@Biotechnology] industry is $2.63B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CLGN’s FA Score shows that 1 FA rating(s) are green whileCYTO’s FA Score has 1 green FA rating(s).

  • CLGN’s FA Score: 1 green, 4 red.
  • CYTO’s FA Score: 1 green, 4 red.
According to our system of comparison, CYTO is a better buy in the long-term than CLGN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CYTO’s TA Score shows that 7 TA indicator(s) are bullish.

  • CYTO’s TA Score: 7 bullish, 3 bearish.

Price Growth

CLGN (@Biotechnology) experienced а +6.57% price change this week, while CYTO (@Biotechnology) price change was +22.02% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.98%. For the same industry, the average monthly price growth was +8.91%, and the average quarterly price growth was +90.55%.

Reported Earning Dates

CLGN is expected to report earnings on May 23, 2024.

CYTO is expected to report earnings on Nov 17, 2022.

Industries' Descriptions

@Biotechnology (+4.98% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for CLGN with price predictions.
OPEN
A.I.dvisor published
a Summary for CYTO with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
CLGN($61.3M) has a higher market cap than CYTO($3.77M). CLGN YTD gains are higher at: -16.275 vs. CYTO (-41.092). CLGN has higher annual earnings (EBITDA): -5.87M vs. CYTO (-22.48M). CLGN has more cash in the bank: 22.3M vs. CYTO (49.6K). CLGN (3.35M) and CYTO (3.47M) have identical debt. CLGN has higher revenues than CYTO: CLGN (10.8M) vs CYTO (120K).
CLGNCYTOCLGN / CYTO
Capitalization61.3M3.77M1,627%
EBITDA-5.87M-22.48M26%
Gain YTD-16.275-41.09240%
P/E Ratio476.19N/A-
Revenue10.8M120K9,000%
Total Cash22.3M49.6K44,960%
Total Debt3.35M3.47M97%
FUNDAMENTALS RATINGS
CLGN vs CYTO: Fundamental Ratings
CLGN
CYTO
OUTLOOK RATING
1..100
433
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
17
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
95100
PRICE GROWTH RATING
1..100
6965
P/E GROWTH RATING
1..100
1100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

CYTO's Valuation (17) in the Biotechnology industry is significantly better than the same rating for CLGN (94). This means that CYTO’s stock grew significantly faster than CLGN’s over the last 12 months.

CYTO's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CLGN (100). This means that CYTO’s stock grew similarly to CLGN’s over the last 12 months.

CLGN's SMR Rating (95) in the Biotechnology industry is in the same range as CYTO (100). This means that CLGN’s stock grew similarly to CYTO’s over the last 12 months.

CYTO's Price Growth Rating (65) in the Biotechnology industry is in the same range as CLGN (69). This means that CYTO’s stock grew similarly to CLGN’s over the last 12 months.

CLGN's P/E Growth Rating (1) in the Biotechnology industry is significantly better than the same rating for CYTO (100). This means that CLGN’s stock grew significantly faster than CYTO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CYTO
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Momentum
ODDS (%)
Bullish Trend 1 day ago
89%
MACD
ODDS (%)
Bullish Trend 1 day ago
82%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
82%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
84%
Advances
ODDS (%)
Bullish Trend 4 days ago
83%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
84%
View a ticker or compare two or three
Ad is loading...
CYTODaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NVCR15.630.99
+6.76%
NovoCure Limited
ENTX1.640.10
+6.49%
Entera Bio Ltd
SENEA56.882.11
+3.85%
Seneca Foods Corp
JNJ158.190.23
+0.15%
Johnson & Johnson
CBSH53.20-0.13
-0.24%
Commerce Bancshares

CLGN and

Correlation & Price change

A.I.dvisor tells us that CLGN and NVIVQ have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CLGN and NVIVQ's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CLGN
1D Price
Change %
CLGN100%
+2.29%
NVIVQ - CLGN
27%
Poorly correlated
+4.61%
CLLS - CLGN
25%
Poorly correlated
-0.67%
VOR - CLGN
25%
Poorly correlated
+7.24%
CVAC - CLGN
24%
Poorly correlated
-0.66%
AVXL - CLGN
24%
Poorly correlated
+0.40%
More

CYTO and

Correlation & Price change

A.I.dvisor tells us that CYTO and SILO have been poorly correlated (+28% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CYTO and SILO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CYTO
1D Price
Change %
CYTO100%
-12.77%
SILO - CYTO
28%
Poorly correlated
+2.09%
COGT - CYTO
28%
Poorly correlated
+3.07%
AFMD - CYTO
23%
Poorly correlated
-0.56%
BBIO - CYTO
22%
Poorly correlated
+0.19%
ARQT - CYTO
22%
Poorly correlated
+3.13%
More